Danske Bank A S acquired a new position in shares of Progyny, Inc. (NASDAQ:PGNY – Free Report) in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund acquired 528,717 shares of the company’s stock, valued at approximately $15,243,000. Danske Bank A S owned 0.67% of Progyny as of its most recent SEC filing.
Several other large investors also recently made changes to their positions in the business. Caitong International Asset Management Co. Ltd purchased a new stake in Progyny during the 4th quarter worth $25,000. Hantz Financial Services Inc. raised its position in Progyny by 79.4% in the fourth quarter. Hantz Financial Services Inc. now owns 1,676 shares of the company’s stock valued at $43,000 after purchasing an additional 742 shares during the period. Quarry LP lifted its stake in shares of Progyny by 2,004.1% during the third quarter. Quarry LP now owns 3,598 shares of the company’s stock worth $77,000 after purchasing an additional 3,427 shares in the last quarter. Canada Pension Plan Investment Board acquired a new position in shares of Progyny during the second quarter worth about $77,000. Finally, New Age Alpha Advisors LLC purchased a new stake in shares of Progyny in the fourth quarter worth about $94,000. Institutional investors and hedge funds own 94.93% of the company’s stock.
Insiders Place Their Bets
In related news, CFO Mark S. Livingston sold 2,517 shares of the stock in a transaction dated Thursday, June 4th. The shares were sold at an average price of $25.50, for a total transaction of $64,183.50. Following the sale, the chief financial officer owned 74,688 shares in the company, valued at $1,904,544. This represents a 3.26% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Cheryl Scott sold 7,439 shares of the firm’s stock in a transaction dated Monday, June 1st. The stock was sold at an average price of $26.39, for a total transaction of $196,315.21. Following the completion of the transaction, the director directly owned 19,772 shares in the company, valued at $521,783.08. This represents a 27.34% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders sold 19,063 shares of company stock worth $489,413. Corporate insiders own 9.90% of the company’s stock.
Wall Street Analysts Forecast Growth
Check Out Our Latest Stock Analysis on Progyny
Progyny Stock Performance
NASDAQ:PGNY opened at $25.96 on Friday. The company has a market capitalization of $1.99 billion, a price-to-earnings ratio of 28.22, a price-to-earnings-growth ratio of 1.85 and a beta of 1.01. Progyny, Inc. has a one year low of $16.10 and a one year high of $33.06. The stock has a 50-day simple moving average of $29.15 and a 200 day simple moving average of $23.50.
Progyny (NASDAQ:PGNY – Get Free Report) last issued its earnings results on Thursday, August 6th. The company reported $0.55 EPS for the quarter, topping the consensus estimate of $0.33 by $0.22. Progyny had a return on equity of 15.98% and a net margin of 6.00%.The company had revenue of $350.51 million during the quarter, compared to analyst estimates of $349.05 million. During the same quarter last year, the firm earned $0.19 EPS. The business’s revenue was up 5.3% on a year-over-year basis. Progyny has set its Q3 2026 guidance at 0.500-0.520 EPS and its FY 2026 guidance at 2.040-2.100 EPS. On average, equities research analysts forecast that Progyny, Inc. will post 1.19 EPS for the current fiscal year.
Progyny announced that its Board of Directors has initiated a stock repurchase program on Tuesday, May 26th that authorizes the company to repurchase $200.00 million in outstanding shares. This repurchase authorization authorizes the company to reacquire up to 10.3% of its shares through open market purchases. Shares repurchase programs are generally an indication that the company’s management believes its stock is undervalued.
Progyny Company Profile
Progyny, Inc is a New York-based fertility benefits management company that partners with employers and health plans to design and administer comprehensive family-building programs. The company’s digital health platform integrates clinical expertise, patient support tools and data analytics to help members navigate fertility treatments, from in vitro fertilization (IVF) and egg freezing to surrogacy and adoption. By focusing on outcomes-based care, Progyny aims to improve success rates while controlling costs for its clients.
The core of Progyny’s offering is its proprietary Smart Cycle® benefit, which bundles clinical, emotional and logistical support into a single package.
Featured Articles
- Five stocks we like better than Progyny
- 3 Energy Stocks Raising Dividends as the Sector Surges
- 5 Reasons the S&P 500 Could Keep Rallying Through Year-End
- Walmart’s Post-Earnings Drop Could Be a Buying Opportunity
- The Trade Desk’s Earnings Miss Raises a Bigger Question About Its AI Future
Want to see what other hedge funds are holding PGNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Progyny, Inc. (NASDAQ:PGNY – Free Report).
Receive News & Ratings for Progyny Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Progyny and related companies with MarketBeat.com's FREE daily email newsletter.
